The shares of Stryker and Neogenomics experienced a decline on Tuesday following the announcement that the CEOs of both medtech companies would be stepping down soon. This news led to a noticeable drop in their respective stock prices. It was reported that the CEO transitions at Stryker and Neogenomics caused a negative impact on the market, with investors reacting to the upcoming changes in leadership. The stocks of both companies took a hit, reflecting a downward trend in response to this development.
